RSNA’s $30M policy did not insure against COVID-19 cancellation, judge rules

The Radiological Society of North America is not owed losses it earned after canceling its in-person annual meeting last year due to the COVID-19 pandemic, an Illinois federal judge ruled recently.

U.S. District Judge Robert W. Gettleman pointed to RSNA’s $30 million policy with underwriters at Lloyd’s of London, noting a “clear” communicable disease exclusion in the society’s coverage, Law360 reported July 9.

RSNA had the option to buy communicable disease coverage as part of its event cancellation policy, the news outlet reported, but chose not to.

"The obvious intent is that losses caused by a communicable disease that had been declared a pandemic are excluded from coverage," Judge Gettleman said in the July 8 decision.

The dispute dates back to March, when RSNA accused Llyod’s underwriters of not honoring the event policy, arguing a fair reading of the document resulted in “outright confusion,” according to Law360. In addition to the exclusion, the radiology group said there was also an exception in the policy that made it difficult to determine coverage for communicable diseases.

But Gettleman said that wasn’t the case. He did, however, acknowledge the exclusion contained bad grammar and was poorly written. 

RSNA 2020 was set to take place from November to December at Chicago’s McCormick Place. The in-person cancellation was the first since 1945.

RSNA did not immediately respond to Law360’s request for comment nor an email request from Health Imaging.

Read the full story below.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.